To mark World Prematurity Day 2025, Zutron Pharmaceuticals collaborated with The LittleBigSouls Ghana, a non-governmental organization dedicated to preterm birth awareness and advocacy, to support education and dialogue around preterm birth in Ghana.
As part of the event, Zutron Pharmaceuticals delivered a presentation focused on preterm birth, its common causes, and its wide-reaching impact on families, healthcare systems, and society. The session emphasized the importance of early identification and accurate diagnosis in preventing avoidable preterm deliveries.
The discussion was further enriched by a personal account shared by Madam Fayuda, CEO of Balmaisha Foundation and a mother of a preterm baby. She recounted her experience with Preterm Premature Rupture of Membranes (PROM) caused by a micro-rupture, where initial clinical assessment did not reveal visible amniotic fluid. Despite continued fluid loss, she was reassured and discharged, eventually delivering preterm.
Her story highlighted the clinical challenges associated with diagnosing PROM, particularly in cases of small or intermittent membrane ruptures, where traditional diagnostic methods may be inconclusive. The account underlined the need for objective diagnostic tools to support clinical judgment and reduce the risk of missed or delayed diagnoses.
In response to these challenges, Zutron Pharmaceuticals highlighted its diagnostic solutions, Actim PROM and Actim Partus, which are designed to support clinicians with objective evidence-based testing, improve diagnostic confidence, guide timely clinical intervention, and reduce unnecessary uncertainty.
Zutron Pharmaceuticals reaffirmed its commitment to supporting healthcare professionals through innovation, education, and collaboration, while contributing to efforts aimed at improving maternal and neonatal outcomes and reducing the burden of preterm birth in Ghana.
